Search Results
RETAIN BLADDER: a risk-adapted approach to muscle invasive bladder cancer
Daniel M. Geynisman, MD, explains the risk-adapted approach used in the RETAIN BLADDER trial
Risk-enabled therapy after initiating neoadjuvant chemo allows active surveillance of some MIBC
Are bladder sparing procedures a real advancement in muscle invasive bladder cancer?
Treatment Talk: Clinical Trials for Muscle Invasive Bladder Cancer
Muscle Invasive Bladder Cancer: Detailed end to end treatment options
Highlighting Clinical Trials: Non-Muscle Invasive Bladder Cancer (Part I)
Risk-Adapted TURBT
Case 3: Relapsed Muscle-Invasive Bladder Cancer, FGFR3+
Perioperative treatment strategies for high-risk bladder cancer
Case-Based Panel Discussion: Muscle-Invasive Bladder Cancer
Muscle Invasive Bladder Cancer Treatment